A Randomized, Double-blind, Multicenter, Multiple-dose Study of ALX-0171 Versus Placebo Along With Standard of Care in Japanese Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

Trial Profile

A Randomized, Double-blind, Multicenter, Multiple-dose Study of ALX-0171 Versus Placebo Along With Standard of Care in Japanese Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2018

At a glance

  • Drugs ALX 0171 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Sponsors Ablynx
  • Most Recent Events

    • 02 Mar 2018 According to an Ablynx media release, results from the study are expected in the second half of 2019.
    • 02 Mar 2018 According to an Ablynx media release, a safety review by an independent Data Monitoring Committee will occur prior to proceeding to each higher dose of the treatment.
    • 02 Mar 2018 Status changed from not yet recruiting to recruiting, according to an Ablynx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top